<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12026">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525421</url>
  </required_header>
  <id_info>
    <org_study_id>H1113-30233-01</org_study_id>
    <nct_id>NCT00525421</nct_id>
  </id_info>
  <brief_title>A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind Trial of a Two Week Course of Curcuminoids in Oral Lichen Planus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nita Chainani Wu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2 randomized, placebo-controlled, double-blind trial of a two week course of
      curcuminoids in oral lichen planus will be conducted. 26 consecutive, eligible patients with
      OLP presenting to the oral medicine clinic at the University of California, San Francisco,
      will be enrolled. Study subjects will be randomized to receive either placebo or
      curcuminoids 6000mg/day for 2 weeks in three divided doses of 2000mg three times/day.
      Measurement of signs, symptoms, periodontal status and blood tests including complete blood
      count, liver enzymes, serum c reactive protein and serum interleukin-6 levels will be done
      at baseline and at the end of 2 weeks. A side-effects questionnaire will be administered at
      the 2-week follow-up.

      The Numeric Rating Scale (NRS) will be used to measure symptoms and the Modified Oral
      Mucositis Index (MOMI) to measure clinical signs of OLP. Primary outcome is change in
      symptoms from baseline. Secondary outcomes are change in clinical signs, occurrence of
      side-effects, change in serum C-reactive protein and serum interleukin-6 levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent Change From Baseline to Two Weeks in Symptoms and Signs of Oral Lichen Planus (OLP)</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Numeric Rating Scale (NRS) is patient-reported numerical score for intensity of symptoms (range 0-10, where 0=no oral discomfort and 10=worst imaginable oral discomfort; symptom score over the last 1 week was recorded at baseline, and symptom score since baseline was recorded at follow-up. For Modified Oral Mucositis Index (MOMI) each of 16 oral sites is scored by an examiner for both erythema intensity (range 0-3 where 0=normal, 1=mild, 2=moderate, 3=severe) and area of ulceration (range 0-3 where 0=none, 1=&gt;0-0.25 cm^2, 2= &gt;0.25-1 cm^2, 3=&gt;=1cm^2): right (R) and left (L) buccal mucosa, labial mucosa (upper and lower), lateral tongue (R and L), dorsum of tongue (R and L), ventral tongue and floor of mouth (R and L), maxillary gingiva (R and L), mandibular gingiva (R and L), and soft and hard palate. Total score for clinical signs (MOMI) is the sum of scores for 16 sites; separate scores for erythema and ulceration are the sums of respective scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum C-reactive Protein and Serum Interleukin-6 Levels</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage changes from baseline to two weeks in C-Reactive protein (CLP) and interleukin-6 (IL-6).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Oral Lichen Planus</condition>
  <arm_group>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Curcumin C3 Complex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcuminoids</intervention_name>
    <description>Curcuminoids tablets 2000mg three times per day for 12 days</description>
    <arm_group_label>Curcumin</arm_group_label>
    <other_name>Curcumin C3 Complex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting to the UCSF oral medicine clinic diagnosed with either the
             atrophic or the erosive form of oral lichen planus

          -  Study subjects must have a symptom score between 3 to 8 at the time of entry into the
             study. (Range of scale: zero to ten with zero being no symptoms and ten being the
             worst imaginable symptoms.

          -  Study subjects will have discontinued systemic and/or topical steroids and/or
             curcuminoids for at least 2 weeks before entry into the study.

        Exclusion Criteria:

          -  Pregnancy, lactation or unwillingness to use an effective method of contraception. An
             attempt will be made to ascertain the date of the last menstrual period among
             eligible pre-menopausal women. If pregnancy cannot be ruled out, a pregnancy test
             will be provided to the women before enrollment into the study. - Patients younger
             than 21 years of age.

          -  Patients who cannot return for a follow-up visit at two weeks after enrollment.

          -  Patients who have a medical contraindication to discontinuation of systemic steroids
             eg. those on long term corticosteroid therapy. - Patients with a history of
             gastro-esophageal reflux disease, gastric / duodenal ulcers, or gallstones.

          -  Patients with elevated liver enzymes;

          -  Patients on anticoagulants or antiplatelet medications.

          -  Patients undergoing orthodontic treatment.

          -  Patients who don't read, speak or understand English.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nita Chainani-Wu, DMD, MS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sol Jr. Silverman, MA, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med. 2003 Feb;9(1):161-8. Review.</citation>
    <PMID>12676044</PMID>
  </reference>
  <reference>
    <citation>Chainani-Wu N, Silverman S Jr, Reingold A, Bostrom A, Mc Culloch C, Lozada-Nur F, Weintraub J. A randomized, placebo-controlled, double-blind clinical trial of curcuminoids in oral lichen planus. Phytomedicine. 2007 Aug;14(7-8):437-46. Epub 2007 Jul 2.</citation>
    <PMID>17604143</PMID>
  </reference>
  <results_reference>
    <citation>Chainani-Wu N, Madden E, Lozada-Nur F, Silverman S Jr. High-dose curcuminoids are efficacious in the reduction in symptoms and signs of oral lichen planus. J Am Acad Dermatol. 2012 May;66(5):752-60. doi: 10.1016/j.jaad.2011.04.022. Epub 2011 Sep 9.</citation>
    <PMID>21907450</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 5, 2013</lastchanged_date>
  <firstreceived_date>September 4, 2007</firstreceived_date>
  <firstreceived_results_date>May 22, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Nita Chainani Wu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>curcuminoids</keyword>
  <keyword>oral lichen planus</keyword>
  <keyword>c reactive protein</keyword>
  <keyword>interleukin 6</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lichen Planus</mesh_term>
    <mesh_term>Lichen Planus, Oral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>23 patients with symptomatic oral lichen planus (OLP) presenting to the oral medicine clinic at the University of California, San Francisco (UCSF) between October 2007 and November 2008 were screening for this study.</recruitment_details>
      <pre_assignment_details>3 patients had elevated liver enzymes at baseline and were excluded prior to randomization</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Curcuminoid</title>
          <description>Curcuminoids : Curcuminoids tablets 2000mg three times per day for 12 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo : identical placebo tablets three times per day for 12 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10">Enrollment started october 2007</participants>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Curcuminoid</title>
          <description>Curcuminoids : Curcuminoids tablets 2000mg three times per day for 12 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo : identical placebo tablets three times per day for 12 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="56.2" spread="11.7"/>
                <measurement group_id="B2" value="60.8" spread="8.6"/>
                <measurement group_id="B3" value="58.5" spread="10.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="13"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Symptom Score for OLP</title>
          <description>Numerical Rating Scale (NRS): 0=No oral discomfort, 10=worst imaginable oral discomfort</description>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>NRS 3-5</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>NRS 5.5-8</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Presence of Oral Ulcerations</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Ulcerations at Baseline</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="7"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>No Ulcerations at Baseline</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Past medication for OLP</title>
          <description>Subjects who used medications in the past for OLP</description>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Topical Steroids</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>No Topical Steroids</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Prednisone</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>No Prednisone</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Azathioprine</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>No Azathioprine</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="18"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Any Prior Medication for OLP</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="17"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>No Prior Medication for OLP</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline to Two Weeks in Symptoms and Signs of Oral Lichen Planus (OLP)</title>
        <description>Numeric Rating Scale (NRS) is patient-reported numerical score for intensity of symptoms (range 0-10, where 0=no oral discomfort and 10=worst imaginable oral discomfort; symptom score over the last 1 week was recorded at baseline, and symptom score since baseline was recorded at follow-up. For Modified Oral Mucositis Index (MOMI) each of 16 oral sites is scored by an examiner for both erythema intensity (range 0-3 where 0=normal, 1=mild, 2=moderate, 3=severe) and area of ulceration (range 0-3 where 0=none, 1=&gt;0-0.25 cm^2, 2= &gt;0.25-1 cm^2, 3=&gt;=1cm^2): right (R) and left (L) buccal mucosa, labial mucosa (upper and lower), lateral tongue (R and L), dorsum of tongue (R and L), ventral tongue and floor of mouth (R and L), maxillary gingiva (R and L), mandibular gingiva (R and L), and soft and hard palate. Total score for clinical signs (MOMI) is the sum of scores for 16 sites; separate scores for erythema and ulceration are the sums of respective scores.</description>
        <time_frame>2 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Curcuminoid</title>
            <description>Curcuminoids : Curcuminoids tablets 2000mg three times per day for 12 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Identical placebo tablets three times per day for 12 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline to Two Weeks in Symptoms and Signs of Oral Lichen Planus (OLP)</title>
            <description>Numeric Rating Scale (NRS) is patient-reported numerical score for intensity of symptoms (range 0-10, where 0=no oral discomfort and 10=worst imaginable oral discomfort; symptom score over the last 1 week was recorded at baseline, and symptom score since baseline was recorded at follow-up. For Modified Oral Mucositis Index (MOMI) each of 16 oral sites is scored by an examiner for both erythema intensity (range 0-3 where 0=normal, 1=mild, 2=moderate, 3=severe) and area of ulceration (range 0-3 where 0=none, 1=&gt;0-0.25 cm^2, 2= &gt;0.25-1 cm^2, 3=&gt;=1cm^2): right (R) and left (L) buccal mucosa, labial mucosa (upper and lower), lateral tongue (R and L), dorsum of tongue (R and L), ventral tongue and floor of mouth (R and L), maxillary gingiva (R and L), mandibular gingiva (R and L), and soft and hard palate. Total score for clinical signs (MOMI) is the sum of scores for 16 sites; separate scores for erythema and ulceration are the sums of respective scores.</description>
            <units>percent change</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>NRS</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-22" lower_limit="-33" upper_limit="-14"/>
                  <measurement group_id="O2" value="0" lower_limit="-29" upper_limit="16.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-17" lower_limit="-29" upper_limit="-8.3"/>
                  <measurement group_id="O2" value="0" lower_limit="-10" upper_limit="16.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ulceration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-14" lower_limit="-60" upper_limit="0"/>
                  <measurement group_id="O2" value="0" lower_limit="0" upper_limit="26.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MOMI</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-24" lower_limit="-38" upper_limit="-11"/>
                  <measurement group_id="O2" value="-3.2" lower_limit="-13" upper_limit="9.09"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum C-reactive Protein and Serum Interleukin-6 Levels</title>
        <description>Percentage changes from baseline to two weeks in C-Reactive protein (CLP) and interleukin-6 (IL-6).</description>
        <time_frame>2 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Curcuminoid</title>
            <description>Curcuminoids : Curcuminoids tablets 2000mg three times per day for 12 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: Identical placebo tablets three times per day for 12 days</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Serum C-reactive Protein and Serum Interleukin-6 Levels</title>
            <description>Percentage changes from baseline to two weeks in C-Reactive protein (CLP) and interleukin-6 (IL-6).</description>
            <units>Percent change</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <sub_title>CRP</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0" lower_limit="-21" upper_limit="19"/>
                  <measurement group_id="O2" value="33.3" lower_limit="0" upper_limit="50"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>IL-6</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20.3" lower_limit="-16" upper_limit="60.6"/>
                  <measurement group_id="O2" value="-1.6" lower_limit="-6.1" upper_limit="3.17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <desc>Side effects were recorded using a 10-item questionnaire, complete blood cell count, and measurement of liver enzymes, aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase at the 2-week follow-up visit</desc>
      <group_list>
        <group group_id="E1">
          <title>Curcuminoid</title>
          <description>Curcuminoids : Curcuminoids tablets 2000mg three times per day for 12 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: Identical placebo tablets three times per day for 12 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated liver enzymes</sub_title>
                <description>Liver enzymes (AST, ALT and alkaline phosphatase) assessed for change from normal baseline to abnormal at follow-up. ALT changed form 40 to 44, and from 59 to 64.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nita Chainani-Wu</name_or_title>
      <organization>University of California San Francisco</organization>
      <phone>415-476-2045</phone>
      <email>nita.wu@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
